For patients with IIH, sustainable weight loss offers the most effective and lasting relief from symptoms—and can help ...

New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today ...

On May 7, 2025, the American College of Rheumatology (ACR) released the full guideline for diagnosing, monitoring, and treating lupus nephritis (LN), which appeared in Arthritis & Rheumatology.

New CAR T-cell therapy shows remarkable efficacy in treating relapsed multiple myeloma, achieving high response rates and ...

The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with relapsed or refractory follicular lymphoma. MONDAY, June 23, 2024 (HealthDay News ...

The national capital reported three more Covid-19 related fatalities in the past 48 hours, pushing the city’s death toll to ...

第30届EHA年会定于6月12日-15日在意大利米兰隆重举行。作为欧洲血液学领域规模最大的国际会议，每年都吸引着来自世界各地的专家学者，一起分享并探讨有关血液学的创新理念及最新的科学和临床研究成果。在这个汇聚智慧与才华的舞台上，全球血液学领域的精英们 ...

Regulatory Clearances Support Glaukos' Plans to Advance and Accelerate its Interventional Glaucoma Initiatives Globally Marks ...

In order to lower diastolic blood pressure, you have to lower your overall blood pressure. Both lifestyle and medication treatment options can help you do this.

Research presented at ASCO 2025 highlighted potential treatments for patients with newly diagnosed and relapsed or refractory ...

Idorsia Pharmaceuticals has claimed FDA approval for aprocitentan as a treatment for resistant hypertension, becoming the first drug in the endothelin receptor antagonist class for that indication.